Amy Fogel
Primary Care · Troy, MINPI 1194457598
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.6% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 11.9% — the pattern of someone who eats at a lot of different presentations. Among primary care clinicians in MI with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 242 payments — averaging $19.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$548
- Lilly USA, LLC$509
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$409
- AstraZeneca$309
- Amgen$300
- AbbVie$288
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$190%
- Food & beverage$4,607100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,626 in reported general payments places this provider in the 90th percentile of 292 primary care providers in Michigan.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 11 | $16,921 |
| OzempicSemaglutide | 12 | $14,401 |
| Losartan Potassium | 87 | $1,359 |
| Atorvastatin Calcium | 110 | $1,169 |
| Metoprolol Succinate | 40 | $941 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 16 | $683 |
| Lisinopril | 58 | $567 |
| Simvastatin | 43 | $534 |
| Rosuvastatin Calcium | 54 | $466 |
| Ezetimibe | 24 | $459 |
| Escitalopram Oxalate | 24 | $451 |
| Levothyroxine Sodium | 53 | $448 |
| Mirtazapine | 21 | $397 |
| Amlodipine Besylate | 68 | $383 |
| Omeprazole | 52 | $322 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $40 | $16,92111 claims |
| Novo NordiskOzempic | $548 | $14,40112 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 292 primary care providers in Michigan.
Other primary care in Troy
- Donna HamillGrosse Pointe$17K
- Marie Sighe-NzokouLansing$16K
- Alexandria SchwabBay City$10K
- Amy HenryRochester Hills$10K
- Claire GebaraWaterford$9K
- Vanita RobinsonDetroit$9K
- Mary BoudreauMason$9K
- Kimberly FrazierLansing$8K
- Rachel HetznerMadison Heights$8K
- Katherine HouleMarquette$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.